Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease
| Autor: | Mar Tintoré, Alberto Alain Gabbai, Enedina Maria Lobato de Oliveira, Nilton Amorin de Souza, Denis Bernardi Bichuetti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors neuromyelitis optica multiple sclerosis Severity of Illness Index neuromielite óptica fatores de risco lcsh:RC321-571 doenças desmielinizantes Young Adult Multiple Sclerosis Relapsing-Remitting Recurrence Risk Factors Internal medicine Severity of illness medicine Demyelinating disease esclerose múltipla Humans demyelinating diseases risk factors Age of Onset lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Expanded Disability Status Scale Neuromyelitis optica business.industry Multiple sclerosis Neuromyelitis Optica Odds ratio medicine.disease Surgery Neurology Cohort Disease Progression Female Neurology (clinical) Age of onset Epidemiologic Methods business |
| Zdroj: | Arquivos de Neuro-Psiquiatria, Volume: 71, Issue: 5, Pages: 275-279, Published: MAY 2013 Arquivos de Neuro-Psiquiatria, Vol 71, Iss 5, Pp 275-279 (2013) Arquivos de Neuro-Psiquiatria v.71 n.5 2013 Arquivos de neuro-psiquiatria Academia Brasileira de Neurologia instacron:ABNEURO |
| Popis: | Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies comparing both conditions in a single center have been done.Methods:Comparison of our previously published cohort of 41 NMO patients with 177 RRMS patients followed in the same center, from 1994 to 2007.Results:Mean age of onset was 32.6 for NMO and 30.2 for RRMS (p=0.2062) with mean disease duration of 7.4 years for NMO and 10.3 years for RRMS. Patients with NMO had a higher annualized relapse rate (1.0 versus 0.8, p=0.0013) and progression index (0.9 versus 0.6, p≪0.0001), with more patients reaching expanded disability status scale (EDSS) 6.0 (39 versus 17%, p=0.0036). The odds ratio for reaching EDSS 6.0 and being deceased due to NMO in comparison to RRMS were, respectively, 3.14 and 12.15.Conclusion:Patients with NMO have a more severe disease than patients with RRMS, including higher risk of dying of a demyelinating disease. Embora a neuromielite óptica (NMO) seja reconhecida como mais grave que a esclerose múltipla remitente recorrente (EMRR), existem poucos estudos comparando as duas doenças em um único centro.Métodos:Comparação de nossa coorte publicada de 41 pacientes com NMO com 177 pacientes com EMRR seguidos no mesmo centro, de 1994 a 2007.Resultados:A média de idade inicial foi de 32,6 anos em NMO e 30,2 anos em EMRR (p=0,2062), com tempo médio de doença de 7,4 anos para NMO e 10,3 anos EMRR. Pacientes com NMO apresentaram maior taxa anualizada de surtos (1,0 versus 0,8, p=0,0013) e índice de progressão (0,9 versus 0,6, p≪0,0001), com mais pacientes atingindo EDSS 6,0 (39 versus 17%, p=0,0036). Os riscos relativos de se alcançar 6,0 EDSS e falecer em decorrência de NMO em comparação com EMRR, foram, respectivamente, 3,14 e 12,15.Conclusão:Pacientes com NMO têm uma doença mais grave do que os pacientes com EMRR, incluindo maior risco de morrer de uma doença desmielinizante. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|